Description
⋅ ACRS Aclaris Therapeutics has 3 clinical trials releasing topline data this year and sufficient cash to fund their operations through the end of 2025.
ACRS is in Piper Sandler`s potential 12 biotech takeovers in 2023.
ACRS reached 52 week low today: $5.05.
Analysts Price Targets:
$21 The Goldman Sachs Group
$29 BTIG Research
$38 Cantor Fitzgerald
$43 HC Wainwright
Considering the above, I think ACRS might be an easy +3X!
Looking forward to read your opinion about it.